Voglibose

• UNSPSC Description:

  Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis[1].

• Target Antigen:

  Glycosidase

• Type:

  Natural Products

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/Voglibose.html

• Purity:

  98.0

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)|H2O : 250 mg/mL (ultrasonic)

• Smiles:

  O[C@@H]1[C@@](O)(CO)C[C@H](NC(CO)CO)[C@H](O)[C@H]1O

• Molecular Weight:

  267.28

• References & Citations:

  [1]Kato J, et al. Alpha-Glucosidase Inhibitor Voglibose Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in Diabetic and Obese Mice. Int J Mol Sci. 2020 Mar 23;21(6):2226.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  83480-29-9